Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chong-Jen Yu

Showing results (421-430 of 478) with videos related to

Pageof 48
Sort By:
Frontiers in Oncology|April 3, 2023
Association of smoking and ALK tyrosine-kinase inhibitors on overall survival in treatment-naïve ALK-positive advanced lung adenocarcinomaZhe-Rong Zheng, Hsiu-Ying Ku, Kun-Chieh Chen, et al.
Journal of the Chinese Medical Association : JCMA|January 22, 2024
The long-term outcome of chronic thromboembolic pulmonary hypertension: Pulmonary endarterectomy and balloon pulmonary angioplastyKuo-Ming Yang, Mei-Tzu Wang, Chi-Wei Tao, et al.
The Oncologist|January 16, 2024
Increased Tuberculosis Reactivation Risk in Patients Receiving Immune Checkpoint Inhibitor-Based TherapyHsing-Wu Chen, Yao-Wen Kuo, Chung-Yu Chen, et al.
Journal of Cancer|May 29, 2018
Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in TaiwanShu-Yung Lin, Ching-Yao Yang, Bin-Chi Liao, et al.
Shock (Augusta, Ga.)|February 19, 2015
Severe lymphopenia is associated with elevated plasma interleukin-15 levels and increased mortality during severe sepsisKuei-Pin Chung, Hou-Tai Chang, Shyh-Chyi Lo, et al.
Human Vaccines & Immunotherapeutics|February 19, 2021
The adjuvanted recombinant zoster vaccine is efficacious and safe in Asian adults ≥ 50 years of age: a sub-cohort analysis of the ZOE-50 and ZOE-70 randomized trialsJoon Hyung Kim, John Diaz-Decaro, Ning Jiang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2022
ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or LeptomeningesLaura Q M Chow, Fabrice Barlesi, Erin M Bertino, et al.
Lung Cancer (Amsterdam, Netherlands)|February 19, 2017
Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE studyGee-Chen Chang, Chien-Hua Tseng, Kuo-Hsuan Hsu, et al.
European Journal of Cancer (Oxford, England : 1990)|November 25, 2019
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitorsChing-Yao Yang, Wei-Yu Liao, Chao-Chi Ho, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 21, 2007
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinibJames Bean, Cameron Brennan, Jin-Yuan Shih, et al.
Pageof 48

Showing results (421-430 of 478) with videos related to

Sort By:
Pageof 48
Frontiers in Oncology|April 3, 2023
Association of smoking and ALK tyrosine-kinase inhibitors on overall survival in treatment-naïve ALK-positive advanced lung adenocarcinomaZhe-Rong Zheng, Hsiu-Ying Ku, Kun-Chieh Chen, et al.
Journal of the Chinese Medical Association : JCMA|January 22, 2024
The long-term outcome of chronic thromboembolic pulmonary hypertension: Pulmonary endarterectomy and balloon pulmonary angioplastyKuo-Ming Yang, Mei-Tzu Wang, Chi-Wei Tao, et al.
The Oncologist|January 16, 2024
Increased Tuberculosis Reactivation Risk in Patients Receiving Immune Checkpoint Inhibitor-Based TherapyHsing-Wu Chen, Yao-Wen Kuo, Chung-Yu Chen, et al.
Journal of Cancer|May 29, 2018
Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in TaiwanShu-Yung Lin, Ching-Yao Yang, Bin-Chi Liao, et al.
Shock (Augusta, Ga.)|February 19, 2015
Severe lymphopenia is associated with elevated plasma interleukin-15 levels and increased mortality during severe sepsisKuei-Pin Chung, Hou-Tai Chang, Shyh-Chyi Lo, et al.
Human Vaccines & Immunotherapeutics|February 19, 2021
The adjuvanted recombinant zoster vaccine is efficacious and safe in Asian adults ≥ 50 years of age: a sub-cohort analysis of the ZOE-50 and ZOE-70 randomized trialsJoon Hyung Kim, John Diaz-Decaro, Ning Jiang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2022
ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or LeptomeningesLaura Q M Chow, Fabrice Barlesi, Erin M Bertino, et al.
Lung Cancer (Amsterdam, Netherlands)|February 19, 2017
Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE studyGee-Chen Chang, Chien-Hua Tseng, Kuo-Hsuan Hsu, et al.
European Journal of Cancer (Oxford, England : 1990)|November 25, 2019
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitorsChing-Yao Yang, Wei-Yu Liao, Chao-Chi Ho, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 21, 2007
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinibJames Bean, Cameron Brennan, Jin-Yuan Shih, et al.
Pageof 48